Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital…
Continue Reading-
Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™
Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…
Continue Reading -
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…
Continue Reading -
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a…
Continue Reading -
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex…
Continue Reading -
Cardior Announces First Patient Dosed in Phase 2 Study
Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding…
Continue Reading -
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Stockholm, Sweden, 12 July 2022 – Gesynta Pharma AB today announces that all patients have…
Continue Reading -
Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension
Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted…
Continue Reading -
Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension
Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro...
Continue Reading -
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG…
Continue Reading